Edition:
India

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

4.16USD
19 Jan 2018
Change (% chg)

$-0.09 (-2.12%)
Prev Close
$4.25
Open
$4.29
Day's High
$4.41
Day's Low
$4.15
Volume
107,415
Avg. Vol
221,506
52-wk High
$16.65
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL, 7 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS.PROTEOSTASIS THERAPEUTICS INC - 28-DAY STUDY CONTINUES TO CONFIRM SAFETY PROFILE OF PTI-428 IN THAT IT WAS GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - PTI-808 WAS FOUND TO BE GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - RESULTS OF PTI-428 MEET EFFICACY ENDPOINT IN 28-DAY STUDY IN CF PATIENTS ON BACKGROUND ORKAMBI.  Full Article

Proteostasis Therapeutics Q3 loss per share $0.56
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock
Tuesday, 6 Sep 2016 

Proteostasis Therapeutics Inc :Files to say it is offering 4.3 million shares of its common stock.  Full Article

Proteostasis Therapeutics files for common stock offering
Friday, 26 Aug 2016 

Proteostasis Therapeutics Inc : Files for common stock offering of up to $60 million - SEC filing Source: (http://bit.ly/2bDxfUB) Further company coverage: [PTI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

Proteostasis Therapeutics says appointment of James M. Detore as CFO
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Says appointment of James M. Detore as Chief Financial Officer .Detore joins company from Bluebird Bio, Inc.  Full Article

Proteostasis Therapeutics, Inc. Announces Closing of Initial Public Offering
Thursday, 18 Feb 2016 

Proteostasis Therapeutics, Inc:Says closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share.All of the shares sold in the offering were offered by Proteostasis Therapeutics, Inc.The company's shares began trading on the NASDAQ Global Market on February 11, 2016 under the ticker symbol "PTI.".The gross proceeds from the offering are $50.0 million, before deducting underwriting discounts and commissions and expenses associated with the offering payable by the company.Leerink Partners and RBC Capital Markets acted as joint book-running managers.Baird and H.C. Wainwright & Co. acted as co-managers.  Full Article